Long-term pooled data from the pivotal TRUST-I and TRUST-II studies showed similar efficacy, including duration of response and progression-free survival, between CD74 and non-CD74 ROS1 fusion-partner subgroups Among patients who received IBTROZI after prior chemotherapy, response rates remained consistent, offering reassurance for patients who begin chemotherapy before a ROS1 fusion is identified Sept. 15, 2026 -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling so

Enabled by Altruist's integrated CMC development platform, GMP manufacturing and regulatory service capabilities, LP-003 has successfully advanced from concept to potential commercialization. LP-003 is the first innovative drug independently developed by LongBio Pharma to advance to BLA submission. Sept. 14, 2026 -- Altruist Biologics, a world-class contract development and manufacturing organization (CDMO) and wholly owned subsidiary of Innovent Biologics (1801.HK), congratulates its strategic

Shennon Biotechnologies has welcomed a new chief executive and refreshed its cash reserves, both of which will help shepherd the company's transition from early R&D to clinical development. The biotech on Monday raised $12 million and appointed Cyril Konto as CEO, succeeding founder Li Sun, who will transition to president and chief technology officer. Konto previously served as the executive director for early immuno-oncology clinical development at Pfizer, and prior to that, was the director

RYBREVANT plus chemotherapy demonstrates durable benefit with a differentiated approach that dual-targets EGFR and MET Results mark significant progress for a patient population with poor outcomes and a historical five-year survival rate of just 8% Sept. 13, 2026 -- Johnson & Johnson (NYSE: JNJ) today announced results from the final overall survival (OS) analysis of the Phase 3 PAPILLON study evaluating first-line intravenous (IV) RYBREVANT (amivantamab-vmjw) plus carboplatin-pemetrexed chemot

PTK7 Expression Remained Stable Following Standard-of-Care Therapies, Supporting Its Relevance as a Target in Second- or Later-Line EGFR NSCLC Findings Reinforce the Scientific Rationale for HWK-007, Whitehawk's Next-Generation PTK7-Directed ADC Currently in Phase 1 Developmen Sept. 13, 2026 -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved antibody drug conju

The fifteen-month dataset represents the final analysis from the Phase 1/2 study At the Month 15 primary timepoint, SKY-0515-treated patients showed a +1.59-point difference in Composite Unified Huntington's Disease Rating Scale (cUHDRS) change from baseline versus overlap-weighted external natural history control Differences favoring SKY-0515 were statistically significant across all four cUHDRS components – Total Functional Capacity, Total Motor Score, Symbol Digit Modalities Test and Stroop W

Presentation highlights data demonstrating that the dual LSD1/HDAC6 inhibitor achieves rapid and sustained dose-responsive reductions in platelet counts in patients with essential thrombocythemia (ET), with consistent activity also observed in polycythemia vera (PV) and other myeloproliferative neoplasms (MPNs) Sept. 15, 2026 -- Jubilant Therapeutics Inc., a clinical-stage biopharmaceutical company advancing precision therapies for hematological malignancies, today announced the presentation of

Vera Therapeutics is on course to gain full approval of Trutakna (atacicept-vymj) after announcing Tuesday that the drug met all prespecified endpoints at the final efficacy analysis of the Phase III ORIGIN 3 trial in adults with primary IgA nephropathy (IgAN) at risk for disease progression. The news sent company shares up nearly 15% in premarket trading. Trutakna, designed to simultaneously block BAFF and APRIL, gained accelerated FDA approval in July to reduce proteinuria in adults with prim

Ivonescimab Reduced the Risk of Death by 27% Compared to Pembrolizumab HARMONi-2 Demonstrated an Improvement in Median Overall Survival of 8.2 Months PD-L1 High Expression Subgroup: Hazard Ratio = 0.58 Summit is Conducting Global Phase III HARMONi-7 Study in Patients with PD-L1 High-Expressing NSCLC Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. announced that updated data, including overall survival (OS), from the randomized, double-blind Phase III HARMONi-2 tr

Sept. 14, 2026 -- Sapience Therapeutics, Inc., a clinical-stage biotechnology company dedicated to developing first-in-class peptide therapeutics targeting the underlying oncogenic and immune mechanisms driving cancer and pre-cancerous disease, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company an Investigational New Drug (IND) application for ST316 (IND 184073) for the treatment of familial adenomatous polyposis (FAP), a rare inherited disorder associated w